Skip to main content

Advertisement

SpringerLink
Log in

Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

The present study aimed to assess the effects of a COX-2 inhibitor, celecoxib, a HMG-CoA reductase inhibitor, atorvastatin, and the association of both on monocrotaline (MC)-induced pulmonary hypertension in rats. Celecoxib (Cib, 25 mg kg−1 day−1), atorvastatin (AS, 10 mg kg−1 day−1) or vehicle, were given orally, separately or in combination, for 26 days to Wistar male rats injected or not with MC (60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed a severe pulmonary hypertension, with an increase in lung to body weight ratio (L/BW), right ventricular pressure (RVP in mmHg, 31 ± 3 and 14 ± 1 for MC and control groups, respectively, P < 0.05) and right ventricle/left ventricle + septum weight ratio (RV/LV+S) associated with a decrease in acetylcholine- and sodium-nitroprusside-induced pulmonary artery vasodilation in vitro. Hypertensive pulmonary arteries exhibited an increase in wall thickness (wall thickness to external diameter ratio, 0.42 ± 0.01 vs 0.24 ± 0.01 for MC and control groups, respectively, P < 0.001). Whole lung eNOS expression was decreased, and an increase in apoptosis, evaluated by cleaved caspase-3 expression, was evidenced by Western blotting. Cib (RVP in mmHg, 19 ± 3 and 31 ± 3 for MC+Cib and MC groups, respectively, P < 0.05), but neither AS nor AS+Cib significantly limited the development of pulmonary hypertension (P < 0.05), although the three treatments exhibited protective effects against MC-induced lung and right ventricle hypertrophy evaluated by L/BW and RV/(LV+S) ratios, respectively (P < 0.05). AS, Cib and AS+Cib treatments reduced MC-induced thickening of small intrapulmonary artery wall (0.42 ± 0.01, 0.24 ± 0.01, 0.26 ± 0.01 and 0.28 ± 0.01 for MC, MC+AS, MC+Cib and MC+AS+Cib groups, respectively, P < 0.001). In control rats, Cib reduced acetylcholine-induced pulmonary artery vasorelaxation. Treatment of MC rats by either Cib or AS did not modify acetylcholine-induced pulmonary artery relaxation, whereas combination of both drugs significantly worsened it (P < 0.05). AS, but neither Cib nor the combination of both, prevented apoptosis (AS, P < 0.05) and partially restored eNOS expression (AS, P < 0.05) in whole lung of MC rats. In conclusion, celecoxib exhibited beneficial effects against the development of monocrotaline-induced pulmonary artery hypertension and right ventricular hypertrophy. These beneficial effects of celecoxib might be, at least partly, explained by its effects on pulmonary artery thickening and pulmonary hypertrophy, even if it did not show any effect on pulmonary artery vasorelaxation and whole lung eNOS expression or apoptosis. The combination of celecoxib and atorvastatin was unable to prevent MC-induced pulmonary hypertension, decreased endothelium-dependent vasorelaxation and showed a trend toward an increased in RVP that deserves further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Amrite AC, Kompella UB (2008) Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther 324:749–758

    Article  PubMed  CAS  Google Scholar 

  • Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y (2006) Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290:H1960–1968

    Article  PubMed  CAS  Google Scholar 

  • Baber SR, Champion HC, Bivalacqua TJ, Hyman AL, Kadowitz PJ (2003) Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation 108:896–901

    Article  PubMed  CAS  Google Scholar 

  • Bardou M, Goirand F, Marchand S, Rouget C, Devillier P, Dumas JP, Morcillo EJ, Rochette L, Dumas M (2001) Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition. J Cardiovasc Pharmacol 38:325–334

    Article  PubMed  CAS  Google Scholar 

  • Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E (2004) Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2:880–887

    Article  PubMed  CAS  Google Scholar 

  • Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28:1195–1203

    Article  PubMed  CAS  Google Scholar 

  • Campian ME, Hardziyenka M, Michel MC, Tan HL (2006) How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 373:391–400

    Article  PubMed  CAS  Google Scholar 

  • Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O’Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I et al (1999) Rofecoxib [Vioxx, MK-0966; 4-(4¢-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551–560

    PubMed  CAS  Google Scholar 

  • Chida M, Voelkel NF (1996) Effects of acute and chronic hypoxia on rat lung cyclooxygenase. Am J Physiol 270:L872–L878

    PubMed  CAS  Google Scholar 

  • Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70–75

    PubMed  CAS  Google Scholar 

  • Dorfmuller P, Humbert M, Capron F, Muller KM (2003a) Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 20:9–19

    PubMed  Google Scholar 

  • Dorfmuller P, Perros F, Balabanian K, Humbert M (2003b) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358–363

    Article  PubMed  CAS  Google Scholar 

  • El-Haroun H, Bradbury D, Clayton A, Knox AJ (2004) Interleukin-1beta, transforming growth factor-beta1, and bradykinin attenuate cyclic AMP production by human pulmonary artery smooth muscle cells in response to prostacyclin analogues and prostaglandin E2 by cyclooxygenase-2 induction and downregulation of adenylyl cyclase isoforms 1, 2, and 4. Circ Res 94:353–361

    Article  PubMed  CAS  Google Scholar 

  • Fike CD, Kaplowitz MR, Zhang Y, Pfister SL (2005) Cyclooxygenase-2 and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn pigs. J Appl Physiol 98:1111–1118 discussion 1091

    Article  PubMed  CAS  Google Scholar 

  • Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA (2003) Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 285:H938–945

    PubMed  CAS  Google Scholar 

  • Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, Mc Laughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ (2007a) Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 66:1467–1472

    Article  PubMed  CAS  Google Scholar 

  • Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, Hassoun PM (2007b) Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol 292:L1105–L1110

    Article  PubMed  CAS  Google Scholar 

  • Grosch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736–747

    Article  PubMed  CAS  Google Scholar 

  • Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4–15

    Article  PubMed  CAS  Google Scholar 

  • Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M (2006) The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol 373:401–414

    Article  PubMed  CAS  Google Scholar 

  • Hasinoff BB, Patel D, Wu X (2007) The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. Cardiovasc Toxicol 7:19–27

    Article  PubMed  CAS  Google Scholar 

  • Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F (2003) Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 108:2308–2311

    Article  PubMed  CAS  Google Scholar 

  • Hermann M, Shaw S, Kiss E, Camici G, Buhler N, Chenevard R, Luscher TF, Grone HJ, Ruschitzka F (2005) Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 45:193–197

    Article  PubMed  CAS  Google Scholar 

  • Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G (2006) Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 173:1023–1030

    Article  PubMed  Google Scholar 

  • Jacobshagen C, Gruber M, Teucher N, Schmidt AG, Unsold BW, Toischer K, Nguyen Van P, Maier LS, Kogler H, Hasenfuss G (2008) Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction. Eur J Heart Fail 10:334–342

    Article  PubMed  CAS  Google Scholar 

  • Jiang QS, Huang XN, Yang GZ, Dai ZK, Zhou QX, Shi JS, Wu Q (2005) Cardiac hypertrophy induced by prostaglandin F(2alpha) may be mediated by calcineurin signal transduction pathway in rats. Sheng Li Xue Bao 57:742–748

    PubMed  CAS  Google Scholar 

  • Kang KB, Rajanayagam MA, van der Zypp A, Majewski H (2007) A role for cyclooxygenase in aging-related changes of beta-adrenoceptor-mediated relaxation in rat aortas. Naunyn Schmiedebergs Arch Pharmacol 375:273–281

    Article  PubMed  CAS  Google Scholar 

  • Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C (2001) Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 104:945–950

    Article  PubMed  CAS  Google Scholar 

  • Kao PN (2005) Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127:1446–1452

    Article  PubMed  CAS  Google Scholar 

  • Klein T, Eltze M, Grebe T, Hatzelmann A, Komhoff M (2007) Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 75:390–397

    Article  PubMed  CAS  Google Scholar 

  • Laemmli UK, Beguin F, Gujer-Kellenberger G (1970) A factor preventing the major head protein of bacteriophage T4 from random aggregation. J Mol Biol 47:69–85

    Article  PubMed  CAS  Google Scholar 

  • Li M, Liu Y, Dutt P, Fanburg BL, Toksoz D (2007) Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Am J Physiol Lung Cell Mol Physiol 293:L463–471

    Article  PubMed  CAS  Google Scholar 

  • McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL (2007) Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin–atorvastatin–simvastatin study. Am J Physiol Lung Cell Mol Physiol 293:L933–340

    Article  PubMed  CAS  Google Scholar 

  • Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G (2004) Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68:341–350

    Article  PubMed  CAS  Google Scholar 

  • Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O, Bradford A, Fitzgerald DJ (2004) Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2. Circulation 110:2701–2707

    Article  PubMed  Google Scholar 

  • Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G (2006) Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27:589–595

    Article  PubMed  CAS  Google Scholar 

  • Puikuan K, Chunyu Z, Jin F, Chaoshu T, Junbao D (2006) Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow. Heart Vessels 21:169–179

    Article  PubMed  Google Scholar 

  • Rahme E, Barkun AN, Toubouti Y, Bardou M (2003) The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125:404–412

    Article  PubMed  CAS  Google Scholar 

  • Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M (2006) The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 374:195–206

    Article  PubMed  CAS  Google Scholar 

  • Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117

    Article  PubMed  CAS  Google Scholar 

  • Sato H, Bolli R, Rokosh GD, Bi Q, Dai S, Shirk G, Tang XL (2007) The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol 293:H2557–2564

    Article  PubMed  CAS  Google Scholar 

  • Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006) A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151(851):e1–5

    PubMed  Google Scholar 

  • Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114:1028–1035

    Article  PubMed  CAS  Google Scholar 

  • Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF (2006) Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 291:L668–676

    Article  PubMed  CAS  Google Scholar 

  • Thomas HC, Lame MW, Dunston SK, Segall HJ, Wilson DW (1998) Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells. Toxicol Appl Pharmacol 151:236–244

    Article  PubMed  CAS  Google Scholar 

  • Timmers L, Sluijter JP, Verlaan CW, Steendijk P, Cramer MJ, Emons M, Strijder C, Grundeman PF, Sze SK, Hua L, Piek JJ, Borst C, Pasterkamp G, de Kleijn DP (2007) Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 115:326–332

    Article  PubMed  CAS  Google Scholar 

  • Vegh J, Soos G, Csipo I, Demeter N, Ben T, Dezso B, Zeher M, Devenyi K, Gaal J, Szegedi G, Bodolay E (2006) Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 26:264–269

    Article  PubMed  Google Scholar 

  • Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S, Bernardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M (2005) Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 312:945–953

    Article  PubMed  CAS  Google Scholar 

  • Wahn H, Wolf J, Kram F, Frantz S, Wagner JA (2005) The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol 289:H2491–2496

    Article  PubMed  CAS  Google Scholar 

  • Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS (2008) Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122:2115–2124

    Article  PubMed  CAS  Google Scholar 

  • Yang X, Sheares KK, Davie N, Upton PD, Taylor GW, Horsley J, Wharton J, Morrell NW (2002) Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 27:688–696

    PubMed  CAS  Google Scholar 

  • Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, Walsh K (2004) Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110:301–308

    Article  PubMed  CAS  Google Scholar 

  • Yildirir A, Muderrisoglu H (2004) Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2:309–318

    Article  PubMed  CAS  Google Scholar 

  • Zhao WG, Richardson JS (1990) Prostacyclin, thromboxane A2, and hypertension. Clin Invest Med 13:343–352

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université de Bourgogne, Dijon, France

    Zo Rakotoniaina, Pascal Guerard, Frédéric Lirussi, Luc Rochette, Monique Dumas, Françoise Goirand & Marc Bardou

  2. EA 2979, LPPCE, IFR Santé-STIC, Dijon, France

    Zo Rakotoniaina, Pascal Guerard, Frédéric Lirussi, Luc Rochette, Monique Dumas, Françoise Goirand & Marc Bardou

  3. CHU de Dijon, Dijon, France

    Pascal Guerard, Frédéric Lirussi, Monique Dumas, Françoise Goirand & Marc Bardou

  4. INSERM CIC-P 803 de Dijon, Faculté de Médecine, Dijon, 7 bd Jeanne d’Arc, BP 87900, 21079, France

    Marc Bardou

Authors
  1. Zo Rakotoniaina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Guerard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frédéric Lirussi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luc Rochette
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Monique Dumas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Françoise Goirand
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc Bardou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Bardou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rakotoniaina, Z., Guerard, P., Lirussi, F. et al. Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. Naunyn-Schmied Arch Pharmacol 378, 241–251 (2008). https://doi.org/10.1007/s00210-008-0298-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-008-0298-3

Keywords

Search

Navigation